Introduction {#S0001}
============

Symptomatic knee osteoarthritis (OA) is very common among older people.[@CIT0001] Its prevalence in subjects over 60 years-old is 12.2% and is notably higher in women (14.9%) than in men (8.7%). It increases with age, obesity and mechanical stress and leads to considerable social costs.[@CIT0002] Common causes of OA include a disruption of homeostatic state of balanced anabolism and catabolism of the cartilage extracellular matrix with a shift toward a catabolic environment. This eventually leads to macroscopic hyaline cartilage degeneration and synovial overgrowth associated with inflammatory changes and bony hypertrophy (osteophyte formation). According to the OARSI guidelines, the first-line treatment of knee osteoarthritis includes non-pharmacological strategies (exercise programs, dietary weight management and education about OA) and secondly, topical or oral anti-inflammatory drugs, intra-articular hyaluronic acid and steroid injections.[@CIT0003] Unfortunately, these therapies have demonstrated little effect in many patients, as well as undesirable side effects. Moreover, the resulting increase in opioid prescription has likely contributed to a dramatic increase in the number of accidental falls in the elderly with increased morbidity.[@CIT0004] Arthroscopy or knee arthroplasty are often considered when other medical therapies fail to relieve symptoms.[@CIT0005]

Pulsed dose radiofrequency (PDRF) is an evolution of conventional radiofrequency with less or no correlation with neural damage.[@CIT0006] Considerable efficacy in reducing symptoms of knee OA has been established when this technique was applied to genicular[@CIT0007] (GN) or intra-articular (IA) nerves.[@CIT0008],[@CIT0009] In long-standing OA, it results in consistent improvement of reported pain, swelling, and stiffness. PRF creates a neuromodulatory effect, suppressing both excitatory C-fibers activation and the spread of pain impulse at the synaptic junction, in addition to a modulatory effect on pro-inflammatory cytokines.[@CIT0010],[@CIT0011]

The purpose of this retrospective study was to evaluate the effects of PDRF applied to GN or to IA + GN in patients with OA knee pain refractory to conservative treatments. Propensity score matching was used to reduce patients' selection bias and to produce two groups that were comparable in terms of demographic profile and disease characteristics.

Methods {#S0002}
=======

This is a single-center clinical cohort study based on a retrospective analysis of prospectively collected data on 78 consecutive patients with moderate-severe knee OA pain unresponsive to conservative treatment who underwent PDRF. The study was conducted at the Pain Unit of ICS Maugeri Hospital, Pavia, Italy, from January 2018 to December 2018. All participants signed a written informed consent. The study was approved by the hospital's Institutional Ethics Committee and was conducted in accordance with the Declaration of Helsinki. All patients were evaluated before PDRF with a knee x-ray and physical examination to ascertain their eligibility. The diagnosis and classification of knee osteoarthritis' severity were conducted through the Kellgren--Lawrence method.[@CIT0012] Patients with knee pain unresponsive to conservative treatment (physiotherapy, oral analgesics) and intra-articular injection with steroids or hyaluronic acid were included in this study. Radicular pain (mainly L3-L4), pain post-total knee replacement, rheumatoid arthritis, complex regional pain syndrome or history of intra-articular injection with steroid or hyaluronic acid within the previous 3 months were considered as exclusion criteria. All enrolled patients underwent a successful diagnostic genicular nerve block with local anesthetic (Lidocaine 1%, 2 mL) prior to PDRF.[@CIT0013]

Patients {#S0002-S2001}
--------

Patients were assigned to PDRF GN or PDRF IA + GN according to physicians' preference and experience with the technique used.

An outcome investigation was performed in both groups at 3 and 6 months following the procedures. Pain intensity (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Patient Global Impression of Change (PGIC) scores were obtained before PDRF and at each follow-up.

Technique {#S0002-S2002}
---------

PDRF GN and PDRF IA + GN were performed with a 22G × 100 mm needle (NeuroTherm^TM^, Medipoint GmbH, Hamburg, Germany) with 10 mm active tip. Fluoroscopic confirmation of the needle position was used for PDRF IA, while both fluoroscopic and ultrasound assessment of topographical localization of superior lateral, superior medial and inferior medial genicular nerve branches were used for PDRF GN. The superior medial genicular nerve curves around the femoral shaft pass on the femoral medial epicondyle to descend 1 cm anterior to the adductor tubercle, where the needle was placed. The inferior medial genicular nerve is situated around the tibial medial epicondyle and was found at the tibial insertion of the medial collateral ligament. The superior lateral genicular nerve was found at the junction between the femoral shaft and the femoral lateral epicondyle. Nerve localization was confirmed with stimulation at ≤0.4mV, 50 Hz. PDRF was performed using the following parameters: 1200 pulses at high voltage (45 V), with 20 ms duration followed by 480 ms silent phases.

Statistical Analyses {#S0002-S2003}
--------------------

Propensity score matching analysis was used with the nearest matching algorithm (1:1 ratio, caliper value= 0.2). Patients' characteristics selected for the matching analysis were: age, body mass index (BMI), basal NRS, basal WOMAC total score and Kellgren--Laurence knee OA grade.

Comparisons between the two groups were carried out with a Mann--Whitney test (*U*-test), after evaluating the normality of the distribution with the Kolmogorov--Smirnov test.

The differences of the quantitative variables at different time points were analyzed with ANOVA for repeated measures with Bonferroni adjustment for multiple comparisons. A p-value \<0.05 was considered statistically significant. Data are expressed as mean ±SD. STATA V.15 (STATA Corp., Texas, USA) was used for the analyses.

Results {#S0003}
=======

112 patients with knee OA pain were screened and 34 did not meet the inclusion criteria. The reason for exclusion included: histories of steroid or hyaluronic acid intra-articular injections within 3 months (13 patients), L3-L4 radiculopathy (7 patients), pain following total knee replacement (7 patients), rheumatoid arthritis (6 patients) and complex regional pain syndrome type 1 (1 patient). Therefore, 78 patients met the inclusion criteria. Propensity score matching analysis resulted in 27 PDRF GN and 27 PDRF IA + GN matched cases, which comprise the study population used for comparisons. Age, BMI, basal NRS, basal WOMAC total score and radiographic disease severity were compared within the matched PDRF GN and PDRF IA + GN groups to evaluate the accuracy of the matching process. No statistically significant difference was observed in any of the above parameters, as demonstrated in [Table 1](#T0001){ref-type="table"}. Female patients accounted for the majority of the sample (72%). Table 1Population Variables. Comparison of Clinical Characteristic Between the PDRF GN and PDRF IA + GN Groups after the matching processPopulation VariablesPDRF GN (n=27)PDRF IA + GN (n=27)pAge75.3±7.976.8±9.450.44BMI27.1±5.626.5±4.90.61NRS basal9.2±0.979.1± 0.960.73WOMAC total score (basal)71.8±14.672.27± 13.50.91Radiographic knee OA severity Grade 2870.76 Grade 314130.59 Grade 4570.51

A significant reduction in NRS score was reported in both groups at 3 months (p\<0.001) and 6 months (p\<0.001) compared to the baseline (PDRF GN: baseline NRS 9.2±0.97, 3 months NRS 4.5±1.63, 6 months NRS 7.2±2.68; PDRF IA + GN: baseline NRS 9.1±0.96, 3 months NRS 2.7±1.71, 6 months NRS 6±2.0). At 3 months, the PDRF IA + GN group's NRS was significantly lower than PDRF GN group's NRS (p\<0.0001). At 6 months, the same results were confirmed although weakened (p=0.006) ([Figure 1](#F0001){ref-type="fig"}). Figure 1Pain intensity measured with a numerical rating scale (NRS) at 3 and 6 months after PDRF GN or PDRF IA + GN. The significant reduction observed at 3 months (p\<0.0001) was maintained, although weakened, at 6 months (p=0.006).

No change in WOMAC pain was found in the PDRF GN group at 3 months (p=0.40) and 6 months after the treatment (p=0.52). Otherwise, WOMAC pain was significantly reduced at 3 months in the PDRF IA + GN group (WOMAC pain baseline 10.12±3.14, WOMAC pain three months 6.25±2.44, p=0.0001). Moreover, WOMAC pain was reduced in PDRF IA + GN group compared to PDRF GN at 3 months (p=0.005) ([Figure 2](#F0002){ref-type="fig"}).

WOMAC stiffness was improved only at 3 months in the PDRF IA + GN group compared to baseline (WOMAC stiffness baseline 4.96±1.83, WOMAC stiffness three months 3.71±1.23, p=0.007) and no changes were found at different time points for PDRF GN. WOMAC stiffness was reduced in PDRF IA + GN group compared to PDRF GN only at 3 months (p=0.02) ([Figure 2](#F0002){ref-type="fig"}).

WOMAC function was improved only in the PDRF IA + GN group at 3 months after the treatment (WOMAC function baseline 55.08±14.52, WOMAC function three months 41.04±11.70, p=0.0006). No differences in WOMAC function were found between the two treatments at different time points ([Figure 2](#F0002){ref-type="fig"}). The WOMAC total score was significantly improved only in the PDRF IA + GN group at 3 months (p\<0.001). Figure 2Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)showed an improvement in pain, stiffness, and function at 3 months post-procedure in the PDRF IA + GN group. WOMAC pain and WOMAC stiffness were significantly improved in the PDRF IA + GN group compared to PDRF GN (see the text). No differences were found for WOMAC function. The WOMAC total score was significantly improved only in the PDRF IA + GN group at 3 months.

Patients reported a longer period of pain relief following PDRF IA + GN (6.75±2.42 months) compared to PDRF GN (4.31±2.85 months, p\<0.001). PGIC score was also better in PDRF IA + GN (PDRF GN 1.8±0.93 vs PDRF IA + GN 2.5±0.81, p=0.005).

Ten patients suffering from knee OA pain mainly located at the femoropatellar joint and confirmed by radiological degenerative findings did not experience any significant pain relief following PDRF. No patients developed significant complications after PDRF during the follow-up period.

Discussion {#S0004}
==========

This study compares the efficacy of PDRF GN versus PDRF IA + GN in patients with moderate-severe knee OA pain unresponsive to conservative treatment. Pain intensity and knee function were analyzed at 1 and 3 months postprocedure follow-up.

PDRF has no neurodestructive effects since it maintains tissue temperature under 42°C, which is below the irreversible tissue damage threshold.[@CIT0014] However, histological studies demonstrated ultrastructural changes in the C and Aδ nociceptive fibers after PDRF.[@CIT0015],[@CIT0016]

On the contrary, intra-articular application of PDRF reduces the response of C fiber along with a reduction of the pro-inflammatory cytokines such as interleukin-1β and interleukin-6.[@CIT0017] As suggested by Sluijter et al, the therapeutic effect of PDRF IA is related to the action of electric fields on immune cells. In fact, in joints with an "open" geometry such as the knee the deflection of the current by bony surfaces forcing the electric filed to remain inside the joint space is very limited.[@CIT0011]

Serdar and colleagues investigated the use of ultrasound-guided PDRF GN and demonstrated a 50% pain reduction after 12 weeks with an improvement of WOMAC scores.[@CIT0007] Similarly, Masala et al investigated the effectiveness of intra-articular knee PDRF in patients with chronic knee pain unresponsive to conservative therapies and reported an improvement in pain intensity and WOMAC up to 1 year after the procedure.[@CIT0008] El-Hakeim et al recently reported in a randomized controlled trial that genicular nerve radiofrequency is not only effective for pain reduction and knee function improvement, but is superior to conventional medical therapy.[@CIT0018]

Our data addressed the results of two different PDRF procedures at 3 and 6 months follow-up. PDRF GN and PDRF IA + GN were both able to significantly reduce NRS scores at 3 months (p\<0.001) and 6 months (p\<0.001) compared to the baseline. WOMAC pain, WOMAC function, WOMAC stiffness and WOMAC total score were significantly improved only in the PDRF IA + GN group at 3 months following the treatment. Moreover, the PDRF IA + GN group demonstrated a better outcome in terms of pain reduction and WOMAC at 3 months compared to the PDRF GN group. The PDRF IA + GN group had a longer period of pain relief and better patient global impression of change at 6 months following treatment compared to the group receiving PDRF GN alone.

This is the first study that describes the association of the two techniques, although further investigations through randomized controlled trials are needed to confirm our findings.

A possible explanation for the increased efficacy of PDRF IA + GN in our patients could be related to the increased electromagnetic field that can act on capsular and genicular nerves, both of which are involved in knee pain nociception.[@CIT0019] Moreover, the total amount of energy delivered to knees' anatomical structures with PDRF IA + GN is greater than PDRF GN as a monotherapy. As recently published, a bipolar PDRF IA seems to be more advantageous in reducing chronic knee pain and functional recovery compared with the unipolar approach.[@CIT0009] Eyigor et al reported knee pain reduction but unmodified functional affects (no change in WOMAC, 20 m walking and 6-min walk test) after PDRF IA.[@CIT0020] Karaman and his group confirmed the global effect of knee pain reduction after PDRF IA but they did not investigate the impact of this technique on knee function.[@CIT0021] An improvement in knee's function after PDRF associated with viscosupplementation was reported by Filippiadis et al.[@CIT0017] Unfortunately, the authors analyzed the knee function and mobility only with patients' verbal reports without standardized scales. Based on these findings, it is reasonable to hypothesize that PDRF IA can reduce pain but it is probably not effective alone in improving knee function.

PDRF techniques are effective treatments for knee OA pain non-responsive to conservative measures. Nevertheless, a standardization of the technique is needed to allow definitive acceptance of PDRF as a treatment available for knee OA. Due to the complex origin of knee joint pain, it is generally recommended to perform a nerve block with local anesthetics before PDRF as confirmed by McCormick et al.[@CIT0022] Surprisingly, a recently published study by the same authors showed that the anesthetic block did not improve the patient selection and the rate of radiofrequency treatment success.[@CIT0023]

Although a propensity score matching analysis could be considered comparable to a randomized trial,[@CIT0024] this study still has limitations. The first is the absence of true randomization between the two PDRF treatment groups. In our study, physicians were permitted to treat patients with PDRF GN or PDRF IA + GN at their own desire. This can cause a possible degree of investigator bias. However, the utilization of a propensity matching technique was useful to reduce the likelihood of such bias. Hence, if we consider [Table 1](#T0001){ref-type="table"}, we can see that the two matched groups presented the same preoperative characteristics. Second, our Center did not program any short term follow-up (at 4 and 8 weeks) for these patients. Consequently, data on the immediate post-treatment period are lacking, and the retrospective nature of this study does not allow us to obtain the data needed to ascertain immediate post-treatment effects. Another possible limitation of this study is that the patients' outcomes have been evaluated only according to the WOMAC scale, the NRS and the PGIC scores. As reported in the literature, additional measures such as the Chair Stand test or the time 20 m walk test could have been used to even better characterize the functional improvement of these patients.[@CIT0025]

This study is retrospective in nature. Accordingly, a future prospective investigation will be required to substantiate the superiority of one technique compared to the other. Nonetheless, the differences identified between the two groups seem to indicate an additive effect of PDRF IA+ GN compared to PDRF GN.

It is noteworthy that patients from both groups who experienced no benefit after PDRF treatment originally manifested pain mainly concentrated at the femoropatellar joint, and simultaneously demonstrated radiographic indicators of patellofemoral joint OA (osteophyte formation, joint space narrowing, subluxation or dislocation, bone destruction). Additional investigations are needed to better understand the ideal PDRF treatment for femoropatellar OA pain.

Conclusions {#S0005}
===========

In the current study, PDRF GN and PDRF IA + GN were both able to significantly reduce the NRS score at 3 months and 6 months compared to baseline. WOMAC pain, WOMAC function, and WOMAC stiffness were significantly improved only in the PDRF IA + GN group at 3 months following the treatment. The PDRF IA + GN group demonstrated a significant WOMAC improvement compared to the PDRF GN group. PDRF IA + GN had a longer period of efficacy compared to PDRF GN and a better PGIC. A prospective analysis is still needed to improve our understanding of the relative benefits of the two PDRF techniques.
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